M&A
Blackstone, Alnylam Ink Collaboration Deal
By Armie Margaret Lee
|
Published: April 15th, 2020
As part of the agreement, Blackstone will pay $1 billion to purchase 50% of Alnylam’s royalties and commercial milestones for inclisiran, an investigational cholesterol treatment.